An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
NCT ID: NCT01168856
Last Updated: 2016-03-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
734 participants
OBSERVATIONAL
2010-09-30
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
NCT02753699
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
NCT01508130
Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals
NCT05062408
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
NCT00308048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic hepatitis C
* participation in Roche DAA treatment protocol for CHC infection
* DAA-associated resistant mutations persisting through to last evaluation in donor protocol , or partial viral response or viral load rebound while on RO5024048 treatment, or sustained virological response \>/= 20 weeks after last dose of study medication in donor study
Exclusion Criteria
* For patients participating in DAA SVR durability: Treatment with any anti-HVC therapy since establishing SVR in the donor study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Jolla, California, United States
Long Beach, California, United States
Sacramento, California, United States
Sacramento, California, United States
San Diego, California, United States
San Francisco, California, United States
Aurora, Colorado, United States
Englewood, Colorado, United States
Bradenton, Florida, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Marietta, Georgia, United States
Honolulu, Hawaii, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Kansas City, Kansas, United States
New Orleans, Louisiana, United States
Detroit, Michigan, United States
Kansas City, Missouri, United States
Lebanon, New Hampshire, United States
Hillsborough, New Jersey, United States
Newark, New Jersey, United States
Manhasset, New York, United States
New York, New York, United States
New York, New York, United States
Providence, Rhode Island, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Newport News, Virginia, United States
Richmond, Virginia, United States
Vancouver, Washington, United States
Darlinghurst, New South Wales, Australia
Kingswood, New South Wales, Australia
Sydney, New South Wales, Australia
Westmead, New South Wales, Australia
Greenslopes, Queensland, Australia
Herston, Queensland, Australia
Woolloongabba, Queensland, Australia
Adelaide, South Australia, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Vienna, , Austria
Salvador, Estado de Bahia, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
Ribeirão Preto, São Paulo, Brazil
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Winnipeg, Manitoba, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Clichy, , France
Créteil, , France
Lille, , France
Marseille, , France
Montpellier, , France
Montpellier, , France
Nice, , France
Paris, , France
Paris, , France
Pessac, , France
Rennes, , France
Toulouse, , France
Vandœuvre-lès-Nancy, , France
Berlin, , Germany
Berlin, , Germany
Frankfurt am Main, , Germany
Hamburg, , Germany
Hanover, , Germany
München, , Germany
Bari, Apulia, Italy
Napoli, Campania, Italy
Bologna, Emilia-Romagna, Italy
Milan, Lombardy, Italy
Milan, Lombardy, Italy
Pavia, Lombardy, Italy
Turin, Piedmont, Italy
Pisa, Tuscany, Italy
Guadalajara, , Mexico
Guadalajara, , Mexico
Monterrey, , Mexico
Christchurch, , New Zealand
Dunedin, , New Zealand
Grafton, , New Zealand
Bydgoszcz, , Poland
Chorzów, , Poland
Lodz, , Poland
Lodz, , Poland
Mysłowice, , Poland
Warsaw, , Poland
Warsaw, , Poland
Wroclaw, , Poland
San Juan, , Puerto Rico
Bratislava, , Slovakia
Palma de Mallorca, Balearic Islands, Spain
Badalona, Barcelona, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
Santander, Cantabria, Spain
A Coruña, La Coruña, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Pontevedra, Pontevedra, Spain
Seville, Sevilla, Spain
San Cristóbal de La Laguna, Tenerife, Spain
Valencia, Valencia, Spain
Dorset, , United Kingdom
Dundee, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-016560-36
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
NV22688
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.